Skip to content

Corporate News Asia

What else is happening in business …

  • About
  • #NEWS
  • #PERSPECTIVES
  • Contact
  • Customer Care

Tag: Medtech

Vicplas FY2024 results subdued, will continue investing in medical devices segment for future growth
28/09/202428/10/2024

Vicplas FY2024 results subdued, will continue investing in medical devices segment for future growth

Vicplas International recorded a revenue of S$102.4 million for FY2024, a decrease of 20.8% from FY2023 due to lower revenue from the medical devices segment. […]

Category: #RESULTS, Vicplas by Head Writer
Hyphens Pharma to bring relief to Shingles sufferers in ASEAN with licensing of Amenalief®
06/06/202406/06/2024

Hyphens Pharma to bring relief to Shingles sufferers in ASEAN with licensing of Amenalief®

Singapore’s leading specialty pharmaceutical and consumer healthcare group, Hyphens Pharma International Limited’s subsidiary, Hyphens Pharma Pte. Ltd., has entered into an exclusive license, development and […]

Category: #NEWS, Hyphens Pharma by Head Writer
Vicplas International reports 1H2024 net profit of S$0.2 million on revenue of S$51.1 million
15/03/202409/10/2024

Vicplas International reports 1H2024 net profit of S$0.2 million on revenue of S$51.1 million

Group revenue for 1H2024 decreased by 23.1% to S$51.1 million due to lower revenue from its medical devices segment and profit after tax decreased by […]

Category: #RESULTS, Vicplas by Head Writer
Hyphens Pharma 3Q2023 net profit drops to S$4 million due to challenging macro environment and record 3Q2022 results
09/11/202306/06/2024

Hyphens Pharma 3Q2023 net profit drops to S$4 million due to challenging macro environment and record 3Q2022 results

Hyphens Pharma Limited has released its quarterly business update for 3Q2023 and 9M2023. 3Q2023 compared to 3Q2022 Revenue in 3Q2023 remained constant at S$42.8 million […]

Category: #RESULTS, Hyphens Pharma by Head Writer
Hyphens Pharma acquires Ardence Pharma in Malaysia
19/10/202306/06/2024

Hyphens Pharma acquires Ardence Pharma in Malaysia

Hyphens Pharma Limited has acquired Ardence Pharma Sdn Bhd, a boutique pharmaceutical company specializing in aesthetic medicine and an existing associate company of Hyphens Group […]

Category: #NEWS, Hyphens Pharma by Head Writer
Vicplas announces new manufacturing facility in Mexico
18/10/202306/06/2024

Vicplas announces new manufacturing facility in Mexico

Vicplas International Ltd’s medical devices segment (“MDS” or “Forefront Medical”) has signed a lease with Parques American Industries, S.A. De C.V., for a new 68,000 […]

Category: #NEWS, Vicplas by Staff Writer
Vicplas International posts FY2023 revenue of S$129.2 million with a profit after tax of S$4.2 million
28/09/202306/06/2024

Vicplas International posts FY2023 revenue of S$129.2 million with a profit after tax of S$4.2 million

Vicplas International announced its FY2023 results, with revenue decreasing slightly by 1.2% to S$129.2 million from S$130.8 million in FY2022 due to lower revenue from […]

Category: #RESULTS, Vicplas by Staff Writer
Hyphens Pharma to develop and commercialise Byfavo® anaesthetic drug with Hana Pharm in Singapore
17/05/202306/06/2024

Hyphens Pharma to develop and commercialise Byfavo® anaesthetic drug with Hana Pharm in Singapore

Hyphens Pharma Limited, Singapore’s leading specialty pharmaceutical and consumer healthcare group, has signed an exclusive sub-license and supply agreement with Hana Pharm Co., Ltd. to […]

Category: #NEWS, Hyphens Pharma by Head Writer
Hyphens Pharma sees soft 1Q2023 due to end of Biosensors distributorship and Vietnam shipment delays
11/05/202306/06/2024

Hyphens Pharma sees soft 1Q2023 due to end of Biosensors distributorship and Vietnam shipment delays

1Q2023 Financial Review Hyphens Pharma Limited’s revenue fell by 15.2% or S$6.0 million from S$39.2 million in 1Q2022 to S$33.2 million in 1Q2023. This was […]

Category: #RESULTS, Hyphens Pharma by Head Writer
Vicplas FY2022 revenue grew 14.8% to S$130.8 million with a net profit of S$8.8 million
23/09/202206/06/2024

Vicplas FY2022 revenue grew 14.8% to S$130.8 million with a net profit of S$8.8 million

Vicplas International FY2022 revenue for its financial year ended 31 July 2022, increased 14.8% to S$130.8 million from S$113.9 million in FY2021. Profit after tax […]

Category: #RESULTS, Vicplas by Head Writer

Posts navigation

1 2

Categories

  • #NEWS
  • #PERSPECTIVES
  • #RESULTS
  • CDW Holding
  • Durapower
  • Heeton
  • Hyphens Pharma
  • IPS Securex
  • Nanofilm Technologies
  • Oiltek
  • Sanli Environmental
  • Sydrogen
  • Valuetronics
  • VCPlus
  • Vicplas
  • Wings Academy

Recent Posts

  • Oiltek International Secures RM45.5 Million Contract in Latin America, Expanding Global Footprint
  • Durapower signs partnership agreement with ARCC to venture into the Australian e-Bus market
  • Vicplas FY2024 results subdued, will continue investing in medical devices segment for future growth
  • Hyphens Pharma launches Ceradan® Advanced Hand Balm specially for hand eczema
  • Oiltek secures new contracts from Africa, Central America and Malaysia worth RM19.5 million

Archives

  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • July 2022
  • June 2022
  • May 2022
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021

Copyright © 2021 - 2023 | All Rights Reserved

Corporate News Asia by Cogent Media Pte. Ltd.